Jagath Reddy Junutula, PhD
Co-founder, President & CEO
Jagath Reddy Junutula, PhD has over 20 years of Oncology drug discovery and development experience and 30 years of experience in the life science research. Jagath obtained his PhD from the Indian Institute of Science, Bangalore, India, and did post-doctoral research at Stanford University. Jagath was at ModMab Therapeutics, Cellerant Therapeutics and Genentech spanning 20 years and responsible in contributing to several INDs and IND-ready programs. His work focusing on drug discovery & development of biologics, including discovery and validation of antibody-drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific T-cell engaging antibodies. He served as a R&D team member of an approved Kadcyla and one of the inventors of an approved Polivy ADCs. He developed a novel THIOMAB technology platform to generate site-specific ADCs to improve the therapeutic utility of antibodies. Jagath was a featured inventor in "Greatest Hits in 20 years of Nature Biotechnology Biomedical Research", Nat. Biotechnol. 2016. Jagath has authored >60 peer-reviewed publications and inventor on >300 patents filed/issued. He received a “Long-standing Contributions to ADC Therapeutic Field” recognition award at the 2017 World ADC Summit, San Diego, CA. Jagath serves as an editorial board member of leading journals, mAbs & ACS Medicinal Chemistry Letters. Jagath is also a co-founder and Board Chairman at Science Gurus (www.sciencegurus.org), a non-profit organization that fosters in developing NextGen Scientists.
Statement: Aarvik is a 20yr dream for the co-founders and Aarvik team is determined to bring first and best-in-class of engineered precision medicines to the cancer patients using its world-class scientific team. We sincerely thank all our mentors, friends, and family for standing by us in the journey of creation of “Aarvik Therapeutics”.